Fig. 5 Metarrestin treatment induces nucleolar structure changes.

Slides:

Advertisements

Similar presentations

Bio 405/505 Cell Nucleus Lectures Session 5 (4/16/09) The Nucleolus: rRNA Gene Organization and Function 1) Koberna et al., J Cell Biol 157 (2002)

Advertisements

Volume 13, Issue 10, Pages (October 2003)

Sec1p requires Boi1/2p for proper localization.

The Nucleolus under Stress

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 2. Bestatin treatment improves tail anatomy and restores lymphatic function. Bestatin treatment improves tail anatomy and restores lymphatic function.

Fig. 7. Role of PDE5 up-regulation in lung cancer–associated PH.

Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1. PARPi and MEKi induce inverse adaptive responses.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 4. Characterization of human liver seed graft morphology.

Fig. 3 BX795 blocks the synthesis of HSV-1 virions.

Intravenous delivery of reovirus to primary and secondary brain tumors

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 2 Systemically released inflammatory factors directly affect HSC-e cell fate. Systemically released inflammatory factors directly affect HSC-e cell.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 1. Aberrant JNK pathway activation in mouse models of ALS and in spinal cord tissue from patients with sporadic ALS. Aberrant JNK pathway activation.

Immunofluorescence staining of virus-infected human placental explants

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5 Acute loss of mitochondrial content after impact is prevented by inhibition of electron transport or critical redox events. Acute loss of mitochondrial.

Fig. 4. MATE1 transcription in RCC.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 7 pDCs are critical for the maintenance of skin fibrosis and for the presence of CXCL4 in the skin. pDCs are critical for the maintenance of skin.

Fig. 6 pDCs infiltrate the skin of BLM-treated mice, and their depletion attenuates skin fibrosis. pDCs infiltrate the skin of BLM-treated mice, and their.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Role of immune and inflammatory cells in lung cancer–associated PH

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 1 BX795 suppresses HSV-1 infection.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Fig. 4 TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine MSCs. TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7. Treatment with DLK inhibitors reduces p-c-Jun and protects against neuronal and synaptic loss in vitro and in ALS mouse models. Treatment with.

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Fig. 2 ALRN-6924 rapidly increases transcription at the p21 locus and affects its bursting dynamics. ALRN-6924 rapidly increases transcription at the p21.

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 3. HECTD2 contains a naturally occurring polymorphism at A19, which mislocalizes to the cytosol. HECTD2 contains a naturally occurring polymorphism.

Fig. 3 CSF1 is expressed in human melanoma.

Yun Wah Lam, Angus I. Lamond, Matthias Mann, Jens S. Andersen

Fig. 6 Photoreceptor cell survival in the RCS rat retina after transplantation with hESC-RPE cell sheets. Photoreceptor cell survival in the RCS rat retina.

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 6 Combination therapy with LVSOD2 and LVshCTGF preserves flap volume and reduces fibrosis after RT. Combination therapy with LVSOD2 and LVshCTGF preserves.

Fig. 8. CCA and ChQ treatment induce accumulation of F-actin rings.

Fig. 6 Metarrestin treatment reduces pre-RNA synthesis and Pol I occupancy at rDNA without changing rDNA chromatin states. Metarrestin treatment reduces.

Ezrin phenotypes in the MVID intestine.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

Fig. 5. Vascularization of human liver seed grafts.

Targeting p53-dependent stem cell loss for intestinal chemoprotection

IFN treatment of human midgestation villous explants induces syncytial knot formation. IFN treatment of human midgestation villous explants induces syncytial.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Presentation transcript:

Fig. 5 Metarrestin treatment induces nucleolar structure changes. Metarrestin treatment induces nucleolar structure changes. (A) Nucleoli lose their typical three substructures, as seen in untreated or DMSO-treated cells (arrows indicate DFC, FC, and GC), and develop nucleolar capping (enlarged inserts) upon treatment with metarrestin in HeLa cells and tumor tissues. Representative electron micrographs are shown for HeLa cells (treated at 1 μM for 24 hours), primary pancreatic tumors, and liver metastases from NSG PANC1 mice treated with vehicle (top) or metarrestin (10 mg/kg) (bottom) for 7 days. Mice were harvested 1 hour after last metarrestin dose (inset shows nucleoli). Scale bars, 1 μm. (B) Quantitative evaluation of the EM images demonstrated that average nucleolar area was reduced in metarrestin-treated cell lines and tissues compared to vehicle control (****P < 0.0001). One hundred nucleoli were randomly selected and analyzed to calculate nucleolar area as {[(largest + shortest diameter)/2]2 × π}. The comparison of mean nucleolar areas was performed using two-tailed Mann-Whitney U test, n = 4 animals per group. (C) The changes in nucleolar architecture induced by metarrestin treatment were reflected in the redistribution of Pol I transcription factor, UBF, into cap-like structures (capping) (white arrows), corresponding to the loss of PNCs (green panel, orange arrows). As shown in the merge panel, the capping of UBF reflects the segregation of the fibrillar components from the granular components, as seen in EM images in (A). (D) Metarrestin interferes with ribosomal biogenesis. An inducible GFP-RPL29–expressing cell line synthesizes GFP-RPL29 when treated with tetracyclin (second panels). When cells were treated with 1 μM metarrestin before tetracycline induction, the newly synthesized proteins accumulated in the nucleoli and nuclei (fourth panels) compared to the DMSO control–treated cells (third panels). (C and D) Scale bars, 5 μm. Kevin J. Frankowski et al., Sci Transl Med 2018;10:eaap8307 Published by AAAS